PlainPharmaWatch

CMS Open Payments · Tool

Roche Sequencing Solutions, Inc. vs Royal Biologics, Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Roche Sequencing Solutions, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 5,222, versus 879 for the other company. Its single largest recorded recipient represents 0.7% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Roche Sequencing Solutions, Inc.
HHI 5,222 · top recipient 0.7%
Ranked #327 of 1,838 companies by HHI
Royal Biologics, Inc.
HHI 879 · top recipient 0.2%
Ranked #1,078 of 1,838 companies by HHI

Payment Overview

Total Payments
$491.0K
% of Industry
0.0%
Transactions
6
Avg per Transaction
$81.8K
Recipients
4
Avg per Recipient
$122.8K
Payment Types
3
Top Payment Type
Royalty or License
Total Payments
$492.4K
% of Industry
0.0%
Transactions
302
Avg per Transaction
$1.6K
Recipients
287
Avg per Recipient
$1.7K
Payment Types
5
Top Payment Type
Royalty or License

Highlighted values indicate the higher figure for each metric.

Total payments compared

Roche Sequencing Solutions, Inc. vs Royal Biologics, Inc. - total reported payments in CMS Open Payments PY2024

Royal Biologics, Inc.$492.4KRoche Sequencing Solutions,…$491.0K

Payment Types Breakdown

Roche Sequencing Solutions, Inc.

Royalty or License $10.0K

2.0%

Compensation for Services Other Than Consulting $2.6K

0.5%

Consulting Fee $1.7K

0.4%

Royal Biologics, Inc.

Royalty or License $225.2K

45.7%

Consulting Fee $171.9K

34.9%

Food and Beverage $12.0K

2.4%

Travel and Lodging $5.5K

1.1%

Entertainment $926.09

0.2%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Roche Sequencing Solutions, Inc.

  1. 1

    BRIGHAM AND WOMENS HOSPITAL

    $10,000.00 · 1 txns

  2. 2

    STEPHEN RENNARD

    $1,722.50 · 1 txns

  3. 3

    RENA XIAN

    $1,659.92 · 1 txns

  4. 4

    PAWEL MROZ

    $900.00 · 1 txns

Royal Biologics, Inc.

  1. 1

    Raz Winiarsky

    $68,400.00 · 13 txns

  2. 2

    Grigoriy Arutyunyan

    $60,848.79 · 4 txns

  3. 3

    Robert Wetzel

    $41,460.40 · 6 txns

  4. 4

    Brad Prybis

    $39,824.91 · 5 txns

  5. 5

    Ki-Hon Lin

    $35,669.07 · 6 txns

Summary Comparison

Metric Roche Sequencing Solutions, Inc. Royal Biologics, Inc.
Total Payments $491.0K $492.4K
% of Industry Total 0.0% 0.0%
Transaction Count 6 302
Avg per Transaction $81.8K $1.6K
Recipient Count 4 287
Avg per Recipient $122.8K $1.7K
Payment Type Count 3 5
Top Payment Type Royalty or License Royalty or License

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.